BOTULINUM TOXIN-A INJECTIONS INTO FACIAL MUSCLES FOR THE TREATMENT OF TEMPOROMANDIBULAR DISORDERS AND BRUXISM: A SYSTEMATIC REVIEW
Main Article Content
Keywords
Disorders, bruxism, growing, injections
Abstract
Background: Currently it has been shown that botulinum toxin is effective for a wide variety of medical conditions, and can be applied for therapeutic purposes as cosmetic. In recent years, there has been a growing trend in the use of this drug substance to control the muscular overactivity of bruxism. The objective of this study was the use of botulinum toxin type A (BTX-A) than traditional methods, by conducting a systematic review of randomized clinical trials (RCTs) published in the health sciences literature.
Materials and Methods: An electronic search was made in the databases of PubMed, Cochrane Library, Google Scholar and LILACS from Jan 2016. Studies that were included were of patients suffering from bruxism and/or TMD, older than 18 years where BTX-A tests were performed on the masseter and / or temporal muscles and the control systems were injections of placebo (saline) or the use of traditional methods for the treatment of bruxism. such as occlusal splints, other medications or cognitive behavioural therapy.
Results: Of the 62 articles sourced, 6 fit the inclusion criteria. These studies show that BTX-A injections can reduce the frequency of bruxism episodes, decrease pain levels and maximum occlusal force generated by this pathology, offer superior efficacy in the treatment of bruxism compared to control groups who were treated with placebo or with traditional methods for the treatment of bruxism.
Conclusion: Infiltrations with BTX-A are a safe and effective treatment for patients with bruxism, so its use is justified in daily clinical practice, especially in patients diagnosed with severe bruxism.
References
2. Manfredini D, Winocur E, Guarda-Nardini L, Paesani D, Lobbezoo F. Epidemiology of bruxism in adults: A systematic review of the literature. J Orofac Pain. 2013;27:99-110.
3. Koyano K, Tsukiyama Y, Ichiki R, Kuwata T. Assessment of bruxism in the clinic. J Oral Rehabil. 2008;35:495-508.
4. Bader G, Kampe T, Tagdae T. Body movement during sleep in subjects with long-standing bruxing behavior. Int J Prosthodont. 2000;13:327-33.
5. Manfredini D, Lobbezoo F. Relationship between bruxism and temporomandibular disorders: A systematic review of literature from 1998 to 2008. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:e25-50.
6. Pierce CJ, Chrisman K, Bennett ME et al. Stress, anticipatory stress, and psychologic measures re- lated to sleep bruxism. J Orofac Pain. 1995;9:51-6.
7. Rugh JD, Barghi N, Drago CJ. Experimental occlusal discrepancies and nocturnal bruxism. J Prosthet Dent. 1984;51:548-53.
8. Lobbezoo F, Naeije M. Bruxism is mainly regulated centrally, not peripherally. J Oral Rehabil. 2001;28:1085-91.
9. Klasser GD, Rei N, Lavigne GJ. Sleep bruxism etiology: The evolution of a changing paradigm. J Can Dent Assoc. 2015;81:f2.
10. Okeson JP. The effects of hard and soft occlusal splints on nocturnal bruxism. J Am Dent Assoc. 1987;114:788-91.
11. Saletu A, Parapatics S, Saletu B, Anderer P, Prause W, Putz H y cols. On the pharmacotherapy
of sleep bruxism: Placebo-controlled polysomnographic and psychometric studies with clonazepam. Neuropsychobiology. 2005;51:214-25
12. Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev. 2017;69:200-35.
13. Urrútia G, Bonfill X. PRISMA declaration: A proposal to improve the publication of systematic reviews and meta-analyses. Med Clin (Barc). 2010;135:507-11.
14. SIGN 50: A guideline developer’s handbook publication 50 [updated November 2015]. In: Scottish Intercollegiate Guidelines Network (SIGN), Edinburgh. Available from http://www.sign.ac.uk.
15. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. In: Higgins JPT, Green S, editors. The Cochrane collaboration. Available from www.cochrane-handbook.org
16. Al-Wayli H. Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin. A prospective and randomized clinical study. J Clin Exp Dent. 2017;9:e112-17
17. Zhang LD, Liu Q, Zou DR, Yu LF. Occlusal force characteristics of masseteric muscles after intramuscular injection of botulinum toxin A (BTX - A) for treatment of temporomandibular disorder. Br J Oral Maxillofac Surg. 2016;54:736-40.
18. Lee SJ, McCall WD Jr, Kim YK, Chung SC, Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: A randomized controlled trial. Am J Phys Med Rehabil. 2010;89:16-23
19. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: A controlled placebo pilot study. Cranio. 2008;26:126-35.
20. Blitzer A, Sulica L. Botulinum toxin: Basic science and clinical uses in otolaryngology. Laryngoscope. 2001;111:218-26.
21. Yin S, Stucker FJ, Nathan CO. Clinical application of botulinum toxin in otolaryngology, head and neck practice (brief review). J La State Med Soc. 2001;153:92-97
22. Kato T, Thie NM, Huynh N, Miyawaki S, Lavigne GJ. Topical review: Sleep bruxism and the role of peripheral sensory influences. J Orofac Pain. 2003;17:191-213
23. Lavigne GJ, Huynh N, Kato T, Okura K, Adachi K, Yao D y cols. Genesis of sleep bruxism: Motor and autonomic-cardiac interactions. Arch Oral Biol. 2007;52:381-4
24. Rao LB, Sangur R, Pradeep S. Application of Botulinum toxin type A: An arsenal in dentistry. Indian J Dent Res. 2011;22:440-45.
25. Fuster Torres MA, Berini Aytés L, Gay Escoda C. Salivary gland application of botulinum toxin for the treatment of sialorrhea. Med Oral Patol Oral Cir Bucal. 2007;12:511-7.
26. Alonso-Navarro H, Jiménez-Jiménez FJ, Plaza-Nieto JF, PiloDe la Fuente B, Navacerrada F, Arroyo-Solera M y cols. Treatment of severe bruxism with botulinum toxin type A. Rev Neurol. 2011;53:73-6.
27. Kim YK, Kim SG, Im JH, Yun PY. Clinical survey of the patients with temporomandibular joint disorders, using Research Diagnostic Criteria (Axis II) for TMD: Preliminary study. J Craniomaxillofac Surg. 2012;40:366-72.
28. Ihde SK, Konstantinovic VS. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: An evidencebased review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:e1-11
29. Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000;131:211-16.
30. Monroy PG, Da Fonseca MA. The use of botulinum toxin-A in the treatment of severe bruxism in a patient with autism: A case report. Spec Care Dentist. 2006;26:37-39.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.